🏆 Finalist — NIH Data Sharing Index (“S-Index”) Challenge

Zachary Ehlinger

Cancer Prevention Institute of California

ORCID: 0000-0003-0849-1089

Also affiliated with Cancer Institute (WIA), Stanford Cancer Institute, Stanford University

MedicineImmunology and Microbiology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile
0Author DataRank

Indexed papers

0in pilot corpus
datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 8 papers. Top paper: “CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell malignancies: a phase 1 trial”.

CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell malignancies: a phase 1 trial

Nature Medicine(2021)10.1038/s41591-021-01436-0
N/A
4.8DataRank · unranked
582 citations

Shabnum Patel, Lori Muffly, Nasheed Hossain, Jean Oak, John H. Baird +44 more

CD22-directed CAR T-cell therapy for large B-cell lymphomas progressing after CD19-directed CAR T-cell therapy: a dose-finding phase 1 study

The Lancet(2024)10.1016/s0140-6736(24)00746-3
N/A
1.4DataRank · unranked
60 citations

John H. Baird, Anne Marijn Kramer, Hrishikesh K. Srinagesh, Shabnum Patel, Annie Kathleen Brown +43 more

Post-infusion CAR TReg cells identify patients resistant to CD19-CAR therapy

Nature Medicine(2022)10.1038/s41591-022-01960-7
N/A
0.828DataRank · unranked
248 citations

Jay Y. Spiegel, Bita Sahaf, Meena Malipatlolla, Zachary Ehlinger, Sreevidya Kurra +25 more

Immune reconstitution and infectious complications following axicabtagene ciloleucel therapy for large B-cell lymphoma

Blood Advances(2021)10.1182/bloodadvances.2020002732
N/A
0.792DataRank · unranked
196 citations

David J. Epstein, John Tamaresis, Zachary Ehlinger, Jay Y. Spiegel, Juliana Craig +18 more

CAR19 therapy drives expansion of clonal hematopoiesis and associated cytopenias

Research Square(2025)10.21203/rs.3.rs-7746241/v1
N/A
0.104DataRank · unranked
1 citations

Mark P. Hamilton, Nick Phillips, Troy Noordenbos, Jan Boegeholz, Takeshi Sugio +32 more

Outcomes following CD22 CAR T-cells in B-ALL: a tale of two manufacturing strategies

Cytotherapy(2025)10.1016/j.jcyt.2025.09.013
N/A
0DataRank · unranked
0 citations

Anne Marijn Kramer, Bonnie Yates, Hao‐Wei Wang, Bita Sahaf, Constance M. Yuan +28 more

CAR19 monitoring by peripheral blood immunophenotyping reveals histology-specific expansion and toxicity

Blood Advances(2024)10.1182/bloodadvances.2024012637
N/A
0DataRank · unranked
24 citations

Erin Craig, Cesar Gentille Sanchez, Alain Mina, John Tamaresis, Nadia Kirmani +27 more

Long-Term Clinical Outcomes and B Cell Immune Reconstitution Following Allo-HCT With Prophylactic, Post-Transplant Rituximab

Transplantation and Cellular Therapy(2024)10.1016/j.jtct.2024.02.025
N/A
0DataRank · unranked
3 citations

Bita Sahaf, Fang Wu, Zachary Ehlinger, Sally Arai, David B. Miklos +1 more